Lund, Sweden, 10 March, 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that Renée Aguiar-Lucander, CEO, Hansa Biopharma, will participate in a fireside chat at DNB Carnegie Healthcare Conference 2026 in Stockholm, at 15:10 PM EDT on Thursday 12 March, 2026. Hansa Biopharma VP Global Corporate Affairs Kerstin Falck will also be attending the event. […]
Phase I results demonstrate favorable safety, sustained target engagement, and early signs of anti-tumor activity Reinforce EP4 receptor antagonism as a validated, high-value strategy to overcome immunotherapy resistance Montreal, Canada – Strasbourg, France – Boston, United States, March 10, 2026: Kainova Therapeutics (“the Company”), a key player for breakthrough treatments in immuno-oncology and inflammation, today […]
Use of numares’ metabolite constellation showed a stable urinary metabolic profile in the first 14 days for living donor recipients, enabling accurate early rejection detection Deceased donor recipients exhibit ischemia‑driven metabolic alterations that transiently mask rejection signals Groundbreaking study was led by researchers at University Hospital Regensburg in conjunction with numares Health Regensburg, Germany, 09 […]
Lund, Sweden, 9 March, 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that Renée Aguiar-Lucander, CEO, Hansa Biopharma, will be participating in a panel discussion titled “The Path to Public: Mastering Your Exit Strategy” at LSX Investival Showcase USA in Miami, at 15:15 PM EDT on Tuesday 10 March, 2026. Hansa Biopharma COO […]
Lund, Sweden, 6 March, 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that Renée Aguiar-Lucander, CEO, Hansa Biopharma, will participate in a fireside chat at Leerink Global Healthcare Conference in Miami, at 13:40 PM EDT on Monday 9 March, 2026. Hansa Biopharma COO and President U.S. Maria Törnsén, and CMO Richard Philipson will […]
